Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027

Voyager Therapeutics, Inc.

2024-Q1 EPS reported -$0.20 revenue$19,516,000

Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.
Cash, equivalents and marketable securities of $400.5M as of March 31, 2024; runway into 2027.
IND clearance from FDA for anti-tau antibody VY-TAU01 for Alzheimer's disease; Phase 1a dosing imminent.
Development candidates selected in GBA1 and Friedreich's Ataxia gene therapy programs with Neurocrine; $8M total milestones triggered.
Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Voyager Therapeutics, Inc. reported first quarter 2024 results: revenue $19.5 million, net income $11.3 million.

Period: first quarter 2024
Revenue: $19.5 million
Net income: $11.3 million
Result: reported results

Exact text from the filing

INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025. First Quarter 2024 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.